Form 8-K - Current report:
SEC Accession No. 0001628280-23-040776
Filing Date
2023-12-05
Accepted
2023-12-05 17:16:17
Documents
14
Period of Report
2023-12-05
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20231205.htm   iXBRL 8-K 32630
2 EX-16.1 arwr8-kacknowledgement.htm EX-16.1 1062
6 arwr8-kacknowledgement001.jpg GRAPHIC 68252
  Complete submission text file 0001628280-23-040776.txt   259029

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20231205.xsd EX-101.SCH 1931
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20231205_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20231205_pre.xml EX-101.PRE 13066
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20231205_htm.xml XML 2829
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 231467585
SIC: 2834 Pharmaceutical Preparations